LifeMD, Inc. Reports Strong Q4 2024 Results

Lifemd, Inc. ( (LFMD) ) has released its Q4 earnings. Here is a breakdown of the information Lifemd, Inc. presented to its investors.

LifeMD, Inc. is a prominent provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across a wide range of health conditions, including weight management and hormone therapy, through a comprehensive digital care platform.

In its latest earnings report, LifeMD announced a significant increase in both revenue and profitability for the fourth quarter of 2024, with consolidated revenues rising by 43% year-over-year to $64.3 million, driven by a 60% increase in telehealth revenue. The company also reported a substantial improvement in adjusted EBITDA, which grew by 78% to $9.0 million.

Key financial highlights include a 27% increase in telehealth active subscribers, reaching approximately 275,000, and a notable rise in telehealth adjusted EBITDA by 396% to $5.9 million. The company ended the year with over $35 million in cash and introduced a positive financial outlook for 2025, projecting consolidated revenue between $265 million and $275 million and adjusted EBITDA between $30 million and $32 million.

LifeMD’s management expressed satisfaction with the company’s growth trajectory, particularly in its weight management program and the integration with LillyDirect to offer more affordable medication options. The upcoming Medicare launch is expected to further drive growth in the weight management sector. Additionally, the company is preparing to expand its offerings with a virtual-first behavioral health service and a women’s health specialty later in the year.

Looking ahead, LifeMD is well-positioned for continued growth and profitability in 2025, with management focused on enhancing its virtual care platform to ensure it remains transparent, affordable, and accessible to all users.